



Imaging biomarkers are key to detecting and treating cancer

Press Release

MEDIAN Technologies Announces New €633,000 Study Award

MEDIAN Technologies accelerates its business development with a newly awarded project for image management in a phase II clinical trial for prostate cancer.

Sophia Antipolis, France – March 13, 2013 – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today it has been selected to provide imaging solutions and services in a phase II clinical trial for prostate cancer. This trial is sponsored by a global biopharmaceutical company.

“We are very proud of this new success with one of the leading pharmaceutical companies worldwide. This project clearly reinforces our strategy, strengthens our commercial positioning, and further demonstrates the growing interest of major biopharmaceutical groups for our cutting-edge imaging technologies,” said MEDIAN’s Chief Executive Officer, Fredrik Brag.

Within the frame of the study, MEDIAN will provide a wide range of imaging services, from trial-specific imaging procedures and charters to image quality control. MEDIAN will also manage the image independent reviews performed by radiologists using the MEDIAN LMS platform. Based on proprietary image processing algorithms, LMS makes the analysis and interpretation of medical imaging data more reliable, less reader-dependent, and easier to accomplish.

As part of the project, imaging data will be acquired in more than 80 clinical sites located in 18 countries worldwide. Anticipated total enrollment is 250 patients with a forecasted project start by year end.

The amount of the project is estimated at €633,000 (eq. \$853,000) for MEDIAN.

This new award builds on the growing success of the company. On March 1, MEDIAN announced the company was selected as an imaging solutions provider for a phase II clinical trials involving more than 100 investigator sites worldwide for a total project amount of €1.4 M (eq. \$1.8 M).

ALMDT
LISTED
NYSE
ALTERNEXT

About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS



MEDIAN

Imaging biomarkers are key to detecting and treating cancer

solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Canon for the development of new technologies, and a strategic partnership with Quintiles to offer integrated imaging services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary in the Boston area.

MEDIAN has received the label "Innovative company" by OSEO and is listed on NYSE Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).

For more information on MEDIAN, please visit: www.mediantechologies.com

CONTACTS

MEDIAN Technologies

Fredrik Brag, CEO
+33 492 906 582
fredrik.brag@mediantechnologies.com

Press

ALIZE RP
Caroline Carmagnol
+ 33 664 189 959
+ 33 142 688 643
caroline@alizerp.com

Christian Berg
+ 33 142 688 641
christian@alizerp.com

Investors

ACTIFIN
Anaïs de Scitivaux
+ 33 156 881 114
adescitivaux@actifin.fr